Agios Pharmaceuticals
-
News
EU APPROVES MITAPIVAT | A New Treatment Milestone for Adults with α- or β-Thalassaemia
This decision is of particular importance because it covers a broad adult thalassaemia population, including both alpha- and beta-thalassaemia and both transfusion-dependent and non-transfusion-dependent disease. According to Agios Pharmaceuticals’ official…
Read More » -
News
FDA APPROVES AQVESME™ (mitapivat) | First Oral Therapy for Anaemia Across All Forms of Thalassaemia
This regulatory decision marks a landmark milestone in the management of thalassaemia, as AQVESME is now the first and only therapy approved in the United States indicated for treating anaemia…
Read More » -
News
CLINICAL NEWS | Agios Meets Clinical Proof-of-Concept in Anaemia Treatment for Adults with Lower-Risk MDS
On Monday, the specialized disease company announced the successful achievement of “proof-of-concept” in a Phase 2a trial involving AG-946, a pyruvate kinase (PK) activator aimed at treating anemia in patients…
Read More » -
News
THAL PALS PODCAST | New Episode on TIF’s NTDT Guidelines Out Now
Dr. Κevin Kuo, MD, MSc, Clinician Investigator, and Μrs. Laurice Levine, Thalassaemia Patient Advocate, talk to TIF’s Executive Director, Dr Androulla Eleftheriou, and Dr. Khaled Musallam, Chief Research Officer, MD,…
Read More »